Results 61 to 70 of about 472,711 (314)

Adaptaquin is selectively toxic to glioma stem cells through disruption of iron and cholesterol metabolism

Molecular Oncology, EarlyView.
Adaptaquin selectively kills glioma stem cells while sparing differentiated brain cells. Transcriptomic and proteomic analyses show Adaptaquin disrupts iron and cholesterol homeostasis, with iron chelation amplifying cytotoxicity via cholesterol depletion, mitochondrial dysfunction, and elevated reactive oxygen species.
Adrien M. Vaquié, Davod R. Shah, Eliane E. S. Brechbühl, Michael McNicholas, Zhaoyang Xu, John H. Stockley, Laura Morcom, Diana Gold Diaz, Gemma C. Girdler, Rachel V. Seear, Gabriel Balmus, Rajiv R. Ratan, Harry Bulstrode, James A. Nathan, Manav Pathania, Kevin M. Brindle, David H. Rowitch   +16 more
wiley   +1 more source

Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease

BMC Medicine, 2007
Background Statins are a class of medications that reduce cholesterol by inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Whether statins can benefit patients with dementia remains unclear because of conflicting results.
Li Nien-Chen, Wang Stanley W, Wolozin Benjamin, Lee Austin, Lee Todd A, Kazis Lewis E   +5 more
doaj   +1 more source

cAMP-Inhibits Cytoplasmic Phospholipase A(2) and Protects Neurons against Amyloid-beta-Induced Synapse Damage [PDF]

, 2015
A key event in Alzheimer’s disease (AD) is the production of amyloid-β (Aβ) peptides and the loss of synapses. In cultured neurons Aβ triggered synapse damage as measured by the loss of synaptic proteins. α-synuclein (αSN), aggregates of which accumulate
Bate, C, Williams, A
core   +2 more sources

Tracking Motor Progression and Device‐Aided Therapy Eligibility in Parkinson's Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To characterise the progression of motor symptoms and identify eligibility for device‐aided therapies in Parkinson's disease, using both the 5‐2‐1 criteria and a refined clinical definition, while examining differences across genetic subgroups.
David Ledingham, Sahana Sathyanarayana, Charlotte B. Stewart, Robyn Iredale, Victoria Foster, Debra Galley, Mark Baker, Nicola Pavese   +7 more
wiley   +1 more source

Use of a rivastigmine transdermic patch in Alzheimer's disease and Parkinson's disease dementia [PDF]

Romanian Journal of Neurology, 2009
Alzheimer’s disease and Parkinson’s disease dementia are becoming a public health issue. Given the therapeutic pitfalls in the elderly, there is a need of effective therapies. Rivastigmine, a cholinesterase inhibitor, emerges as an important agent in the
Lacramioara Perju Dumbrava, Teodor Fischer, Razvan Medrea   +2 more
doaj   +1 more source

Parkinson's disease biomarkers: perspective from the NINDS Parkinson's Disease Biomarkers Program [PDF]

, 2017
Biomarkers for Parkinson's disease (PD) diagnosis, prognostication and clinical trial cohort selection are an urgent need. While many promising markers have been discovered through the National Institute of Neurological Disorders and Stroke Parkinson's ...
Albin, Roger, Alcalay, Roy N., Babcock, Debra, Bowman, F. DuBois, Chen-Plotkin, Alice, David, Karen K., Dawson, Ted M., Dewey, Richard B., Jr., Foroud, Tatiana, German, Dwight, Gwinn, Katrina, Huang, Xuemei, Lungu, Codrin, Petyuk, Vlad, Potashkin, Judith A., Rosenthal, Liana S., Saunders-Pullman, Rachel, Scherzer, Clemens R., Sieber, Beth-Anne, St Hillaire-Clarke, Coryse, Sutherland, Margaret, Swanson-Fischer, Christine, Vaillancourt, David E., Walt, David R., West, Andrew B., Zhang, Jing   +25 more
core   +1 more source

Novel clinicopathological characteristics differentiate dementia with Lewy bodies from Parkinson’s disease dementia

Neuropathology and Applied Neurobiology, 2020
Dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD) known as Lewy body dementias have overlapping clinical and neuropathological features. Neuropathology in both includes combination of Lewy body and Alzheimer’s disease (AD) pathology.
D. Hansen, H. Ling, T. Lashley, J. Foley, C. Strand, Thamir M. Eid, J. Holton, T. Warner   +7 more
semanticscholar   +1 more source

Accelerated Progression of Gait Impairment in Parkinson's Disease and REM Sleep Without Atonia

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective People with Parkinson's disease (PD) and rapid eye movement (REM) sleep without atonia (RSWA) often have more severe gait disturbances compared to PD without RSWA. The association between the presence and expression of RSWA and the rate of progression of gait impairment in PD is unknown.
Sommer L. Amundsen‐Huffmaster, Jae Woo Chung, Maria E. Linn‐Evans, Matthew N. Petrucci, Chiahao Lu, Destiny J. Weaver, Joshua De Kam, Scott E. Cooper, Paul J. Tuite, Aleksandar Videnovic, Michael J. Howell, Colum D. MacKinnon   +11 more
wiley   +1 more source

Psychosocial Adjustment of In-Home Caregivers of Family Members with Dementia and Parkinson’s Disease: A Comparative Study

Parkinson's Disease, 2020
Neurodegenerative diseases such as Parkinson’s and dementia are highly prevalent worldwide. People who suffer from these disorders often receive in-home care and assistance from family members, who must dedicate a considerable amount of time to the care ...
María Cristina Lopes Dos Santos, María Victoria Navarta-Sánchez, José Antonio Moler, Ignacio García-Lautre, Sagrario Anaut-Bravo, Mari Carmen Portillo   +5 more
doaj   +1 more source

Effect of Rivastigmine on Behavioral and Psychiatric Symptoms of Parkinson’s Disease Dementia [PDF]

Journal of Movement Disorders, 2015
Objective A recent study showed that rivastigmine and memantin improved behavioral and psychiatric symptoms of dementia (BPSD) in Alzheimer’s dementia. Furthermore, according to recent guidelines presented by the Movement Disorder Society, rivastigmine ...
Yoon-Sang Oh, Joong-Seok Kim, Phil Hyu Lee   +2 more
doaj   +1 more source